 FREMONT, CA, Aug. 03, 2021 GLOBE NEWSWIRE -- via NewMediaWire -- ABVC BioPharma, Inc. ABVC, a clinical stage biopharmaceutical company developing therapeutic solutions in oncologyhematology, central nervous system CNS, and ophthalmology, today announced the pricing of its firm commitment offering of 1,100,000 Units at an offering price of 6.25 per unit for total gross proceeds of 6.875 million. 